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Drug Content Effects on the Dispersion Performance of
Adhesive Mixtures for Inhalation
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Abstract
The drug content in adhesive mixtures for inhalation is known to influence their dispersion performance, but the direction
and magnitude of this influence depends on other variables. In the past decades several mechanisms have been postulated
to explain this finding and a number of possible interacting variables have been identified. Still, the role of drug content in
the formulation of adhesive mixtures for inhalation, which includes its significance as an interacting variable to other
parameters, is poorly understood. Therefore, the results from a series of drug detachment experiments are presented in
which the effect of drug content and its dependence on flow rate, the mixing time and the type of drug is studied.
Furthermore, it is investigated whether the effect depends on the range within which the drug content is changed.
Quantitative and qualitative multiple order interactions are observed between these variables, which may be explained by a
shifting balance between three different mechanisms. The results therefore demonstrate that accounting for (multiple
order) interactions between variables has to be part of quality by design activities and the rational design of future
experiments.
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Introduction
The therapeutic doses of the drugs used in the local treatment of
asthma and COPD differ substantially. For example, the long-
acting beta agonist formoterol and the anticholinergic tiotropium-
bromide are usually administered in doses from 6 to 18 mg,
whereas for the corticosteroid fluticasone doses from a single
inhalation up to 500 mg are given. The large variation in doses is
reflected in the drug contents that are present in commercially
available inhalation powder formulations. For adhesive mixtures
drug contents typically range from 0.1 to 4% (Tables 1 and 2).
In contrast to the wide range of drug contents in marketed
inhalation products, it is almost common practice to use a fixed
drug to carrier ratio of 1:67.5 (1.46%) in studies on the relationship
between certain variables and carrier based formulation perfor-
mance. This ratio is most likely adopted from earlier carrier based
formulations for the RotahalerH, DiskhalerH and Cyclohaler [1].
Therefore, the choice for this particular drug to carrier ratio seems
to be based on historical reasons, rather than it having a sound
scientific foundation.
Such a scientific foundation may be found in several studies
which have already shown that drug content affects blend
homogeneity and drug detachment from the carrier. Adhesive
mixtures for inhalation can be considered ‘total mixes’, in which a
dynamic process of ordering and randomisation determines the
outcome of the blending process [2]. With increasing drug content
the equilibrium is displaced towards randomisation [2–4], which
results in less homogeneous mixtures that are more prone to
segregation during handling as well [5]. On the upside, this
adverse effect may come along with better drug detachment from
the carrier particles when separation forces are generated, as was
reported for a model interactive system containing smooth
spherical carrier particles [6]. For inhalation formulations that
contain lactose carriers the reported effects of drug content on
dispersion performance are not consistent, however. Beneficial
effects of an increasing drug content from 0.25 to 2.8% on the fine
particle fraction (FPF) from two commercially available inhaler
devices were reported by Steckel et al [7], whereas other
evaluation studies described unfavourable effects as well [8,9].
In explaining the effect of the drug content on the dispersion
performance of adhesive mixtures for inhalation several mecha-
nisms have been postulated. Firstly, so-called active sites on the
lactose carrier surface may become saturated with increasing drug
content [10,11]. This results in a decreasing mass percent of drug
adhering strongly to the carrier surface, which improves drug
particle detachment. Secondly, layer formation or agglomeration
of drug particles with increasing drug content can cause
detachment of large agglomerates rather than single drug particles
if failure of adhesive bonds between the inner drug layer and the
carrier surface occurs during inhalation [6,12–14]. This too may
improve drug detachment, because it increases the magnitude of
the lift and inertial separation forces more so than that of the drug-
carrier interaction forces. Thirdly, a higher drug content increases
the effectiveness of inertial and frictional mixing forces as drug
particles fill up clefts and depressions in the carrier surface [14,15].
By being transferred through the powder bed, this enables such
mixing forces to act effectively as press-on forces on drug particles
that would have found shelter from them in carrier surface
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irregularities at a much lower drug content. It causes the particle
interaction forces to increase by reducing their separation distance
and increasing their contact surface area, and therefore, it causes
drug detachment to be negatively affected [16]. And lastly, it was
hypothesised that with increasing drug content detached particles
may be more likely to collide with neighbouring drug particles to
cause enhanced drug detachment; a mechanism which is referred
to as the ‘collision effect’ [6]. Collision effects may marginally
contribute to improved drug detachment with increasing drug
content, but particularly for irregular lactose surfaces their
relevance is questionable. Therefore, they are not further discussed
in this paper.
Since not all of the aforementioned mechanisms result in
improved drug detachment, the net effect of a change in drug
content depends on which mechanism is dominant under the
given circumstances. Therefore, rather the balance of a number of
different mechanisms determines the effect of drug content than
either of these mechanisms alone, and any variable by which this
balance is affected will be an interacting variable. Some variables
that are suspected to interact with the effect of drug content are the
range within which the drug content is changed [8,9]; the
dispersion principle used and its efficacy (e.g. flow rate) [14,15];
the mixing conditions applied; and the characteristics of the used
carrier product [15]. In addition, agglomerate formation may be
drug dependent, and therefore, so may be the effect of drug
content.
A better understanding of the influence of drug content on
dispersion performance may lead to a more rational approach in
future studies regarding the choice for this variable. Furthermore,
it would help to understand the functionality and performance of
carrier products and marketed formulations and to explain the
results from powder dispersion performance tests that are
presented in literature. The objective of this study is therefore to
deepen the understanding of the effect of drug content on drug
particle detachment from lactose carriers during inhalation. To
this end, a series of drug detachment experiments is performed
with formulations containing a range of drug contents. A special
focus is put on the role of flow rate, the type of drug, the range
within which the drug content is changed and mixing time as
interacting variables. Scanning electron microscopy (SEM) and
laser diffraction analysis are used in an attempt to qualify and
quantify the occurrence of the different mechanisms behind the
effect of drug content.
Materials and Methods
Starting Materials
Alpha lactose monohydrate (Pharmatose 80 M) was kindly
donated by DFE Pharma (Goch, Germany). The micronised drugs
used for this study are salbutamol sulphate (supplied by DFE
Pharma), salmeterol xinafoate and fluticasone propionate (granted
by Novartis, Germany) and budesonide (purchased from Fagron,
The Netherlands). All drugs were passed through a 90 mm sieve to
break up larger agglomerates prior to mixing with the carrier.
Carrier Classification
A lactose carrier with a size fraction of 250–315 mm was
obtained from Pharmatose 80 M by 20 minutes of vibratory
sieving at an amplitude of 1.5 mm (Retsch AS 200 control,
Germany) followed by 15 minutes of air jet sieving (Alpine AS200,
Table 1. Drug contents in commercially available carrier






Eklira Genuair 400 ACL 12600 mg 400 mg 3.08%
Beclometason 100
Cyclocaps
BDP 25000 mg 100 mg 0.40%
Beclometason 200
Cyclocaps
BDP 25000 mg 200 mg 0.79%
Beclometason 400
Cyclocaps
BDP 25000 mg 400 mg 1.57%
Budesonide Easyhaler 200 BUD 7903 mg 200 mg 2.47%
Budesonide Easyhaler 400 BUD 14507 mg 400 mg 2.68%
Budesonide Novolizer 200 BUD 10700 mg 200 mg 1.83%
Budesonide Novolizer 400 BUD 10500 mg 400 mg 3.67%
Flixotide Diskus 100 FP 12500 mg 100 mg 0.79%
Flixotide Diskus 250 FP 12500 mg 250 mg 1.96%
Flixotide Diskus 500 FP 12500 mg 500 mg 3.85%
Formoterol Novolizer 6 FFD 5744 mg 6 mg 0.10%
Formoterol Novolizer 12 FFD 11488 mg 12 mg 0.10%
Formoterol Easyhaler 12 FFD 8000 mg 12 mg 0.15%
Seebri Breezhaler GLY 23600 mg 63 mg 0.27%
Onbrez Breezhaler 150 IM 24800 mg 194 mg 0.78%
Onbrez Breezhaler 300 IM 25000 mg 388 mg 1.53%
Salbutamol Cyclocaps 200 SS 25000 mg 200 mg 0.79%
Salbutamol Cyclocaps 400 SS 25000 mg 400 mg 1.57%
Salbutamol Novolizer 100 SS 11420 mg 120 mg 1.04%
Ventolin Diskus 200 SS 40000 mg 200 mg 0.50%
Serevent Diskus SX 12500 mg 50 mg 0.40%
Spiriva Handihaler 18 mg TBM 5500 mg 22.5 mg 0.41%
ACL = aclidinium bromide; BDP = beclometasone dipropionate;
BUD=budesonide; FP = fluticasone propionate; FFD= formoterol fumarate
dihydrate; GLY = glycopyrronium bromide; IM= indacatarol maleate;
SS = salbutamol sulphate; SX = salmeterol xinafoate; TBM= tiotropium bromide.
doi:10.1371/journal.pone.0071339.t001
Table 2. Drug contents in commercially available carrier based combination preparations.
Preparation Drug 1 Drug 2 Carrier/dose Drug 1/dose Drug 2/dose Drug 1 Drug 2 Total content
Foster NEXThaler BDP FFD 9894 mg 100 mg 6 mg 1.00% 0.06% 1.06%
Seretide Diskus 50/100 FP SX 12500 mg 100 mg 50 mg 0.79% 0.40% 1.19%
Seretide Diskus 50/250 FP SX 12500 mg 250 mg 50 mg 1.95% 0.39% 2.34%
Seretide Diskus 50/500 FP SX 12500 mg 500 mg 50 mg 3.83% 0.38% 4.21%
BDP=beclometasone dipropionate; FP = fluticasone propionate; FFD = formoterol fumarate dihydrate; SX = salmeterol xinafoate.
doi:10.1371/journal.pone.0071339.t002
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Augsburg, Germany). Such a coarse size fraction of the crystalline
carrier material stresses the effect of press-on forces during the
mixing process. It is therefore expected to aid in identifying and
determining the relative significance of this mechanism behind the
effect of drug content on drug detachment. Sieving was performed
under uncontrolled environmental conditions (with relative
humidity values ranging from 25–65%). After sieving, the lactose
was left to rest for at least 2 days before further processing to allow
electrostatic charges to dissipate.
Blend Preparation
Drug-carrier blends were prepared in batches of 25 g at
ambient conditions. To prevent electrostatic charge effects as
much as possible, a stainless steel mixing vessel with a volume of
160 cm3 was used (the filling degree was approximately 20%).
During filling of the vessel the drug was ‘sandwiched’ in between
two equal parts of the lactose carrier after which the powder was
gently pre-blended with a spatula for approximately 20 orbits.
Blends were then further mixed in a Turbula blender (WA
Bachhofen, Basel, Switzerland) at 90 rpm for a total of 2, 10 or 60
minutes. Every two minutes any powder adhering to the mixing
vessel wall was scraped loose and returned into the blend. For
salmeterol and fluticasone, blends containing 0.1, 0.2, 0.4, 1, 2 and
4% of drug by weight were prepared, whereas for salbutamol and
budesonide only drug contents of 0.4% and 4% were used. These
drug contents are representative for the typical range found in
commercial preparations (Tables 1 and 2). However, it is
important to realise that the nature of particle interactions in
adhesive mixtures for inhalation is ultimately determined not so
much by the drug content as by the drug particle density on the
carrier surface. This can be expressed as the drug mass per unit
carrier surface area (i.e. carrier surface payload) or the degree of
carrier coverage relative to a single monolayer. This means that a
comparison between mixtures based on drug content is only valid
if they contain a lactose carrier with the same specific surface area
(and a comparable surface roughness and surface ‘activity’). As will
become clear from the calculated drug contents for monolayer
carrier coverage presented in Table 3, drug contents in this study
are chosen such that carrier coverage values range from 6% (for
the 0.1% fluticasone mixture) to 328% (for the 4% budesonide
mixture), representing sub-monolayer to multilayer carrier cover-
age. It should be noted that these values for the carrier coverage
are based on the assumption of a uniform drug distribution over
the carrier surface, which is unlikely to represent the situation in
practice. Therefore, they should merely be regarded as a rough
indication for the average drug particle density on the carrier
surface.
Content Uniformity Testing
Content uniformity of the blends was tested by randomly taking
20 samples of 2561 mg. Samples were analysed as explained in
the section ‘sample analysis’. Content uniformity was considered
acceptable at relative standard deviations (RSDs) ,3%.
Helium Pycnometry
The density of the drugs was measured by helium pycnometry
(model MVP-1, Quantachrome, USA). Sample sizes ranged
between 5.75 g and 12.35 g. Results are the mean of 4
measurements.
Laser Diffraction Analysis
The particle size distributions (PSDs) of the drugs were
determined by laser diffraction technique with the HELOS BF
diffractometer (100 mm lens, calculations based on the Fraunhofer
theory) after dispersion of the powders with a RODOS disperser at
3 bar (Sympatec, Clausthal-Zellerfeld, Germany). Increasing the
pressure drop to 5 bar did not have any influence on the PSDs
measured, confirming that the primary PSDs were already
obtained at the lower pressure.
The PSDs of salmeterol and fluticasone particles (including
agglomerates) as present on the carrier surface in mixtures
containing 0.1% to 1% of drug were measured by wet laser
diffraction. To prepare saturated aqueous drug solutions, suspen-
sions of fluticasone and salmeterol containing 0.03% polysorbate
80 (Tween 80) were prepared by ultrasonication for at least 30
minutes with a Helma Transsonic 700/H ultrasonic bath (Elma
Hans Schmidbauer, Singen, Germany) and subsequent continuous
stirring. After cooling down to room temperature, 35–40 mL of
these suspensions was passed through a 0.2 mm cellulose acetate
filter. To the saturated solutions 20 mg (for 1% mixtures) to
200 mg (for 0.1% mixtures) of the blends was added to dissolve the
lactose carrier and suspend the drug. For the sample sizes used,
optical concentrations ranged between 6 and 14%. It was checked
that dissolved lactose did not influence the results. Measurements
were performed in the CUVETTE SC-40 module (50 mL cuvette)
with the HELOS BF diffractometer with a 100 mm lens and the
FREE computation mode (Sympatec, Clausthal-Zellerfeld, Ger-
many). A stirring speed of approximately 500 rpm in the cuvette
was used continuously to prevent sedimentation of the suspended
drug particles. After 12 minutes all lactose particles were fully
dissolved for all samples and, immediately afterwards, the PSD of
the suspended drug particles was measured for 10 seconds. The
primary PSDs of fluticasone and salmeterol were measured in a
similar way after a pre-suspension step comprising sonication of
approximately 0.5 mg of the drugs in 2 mL of the saturated
solution for 11 minutes using a 70 W, 42 kHz ultrasonic cleaner
(Electris UC449UP, France). The amount of pre-suspension that
was added to the CUVETTE was titrated to an optical
Table 3. PSDs (n = 2) and densities (n = 4) of the drugs.
Drug X10 X50 X90 V% #5 mm r (g/cm3 (SD)) Monolayer (%)* mparticle (10212 g)**
Salmeterol 0.66 1.41 3.04 99.56 1.23 (0.004) 1.24 1.81
Fluticasone 0.72 1.80 3.99 95.66 1.36 (0.007) 1.75 4.15
Salbutamol 0.63 1.24 2.60 100 1.30 (0.012) 1.16 1.30
Budesonide 0.65 1.36 2.90 99.96 1.25 (0.008) 1.22 1.81
*The drug content for theoretical monolayer coverage is calculated as explained previously [15].
**Drug particle mass is calculated based on the X50 and density of the drugs.
doi:10.1371/journal.pone.0071339.t003
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concentration of around 10%. It was checked that the optical
concentration and characteristic PSD data of the primary particles
thus measured remained constant for at least 12 minutes. Because
wet suspension methods as described here are sensitive to bias
especially from (de-)agglomeration effects, the reliability of the
data from these measurements will be discussed further on.
Scanning Electron Microscopy
Scanning electron micrographs of the drugs and blends were
taken with a JSM-6301F (Jeol, Japan) at an acceleration voltage of
3 kV and probe current 7. Samples were fixed to an aluminium
specimen mount by means of double sided adhesive carbon tape.
For the pure drugs any excess sample was blown from the tape
with pressurised air and excess particles from the blends were
gently tapped (instead of blown) from the specimen mount to avoid
drug particle detachment from the carrier crystals. The drugs were
sputter coated with 10 nm of a gold-palladium alloy, whereas for
the mixture samples a coating thickness of 20 nm was found to be
necessary to prevent charging effects.
Drug Detachment Experiments
An air classifier based test inhaler was used for the drug
detachment experiments [17]. The design of the classifier used is
such that .95% of the carrier particles is retained during the
dispersion measurement. The residual amount of drug present on
the surface of the retained carrier particles after a dispersion
experiment was analysed and normalised to 100% retention
(referred to as carrier residue, CR). The percentage of drug
detached was calculated as 100-CR. Note that drug detachment in
this study refers to the relative amount of drug detached.
Therefore, if drug detachment is concluded to be deteriorated
with increasing drug content, the absolute amount of drug
detached may have increased nonetheless. A dose weight of
2561 mg was used for the dispersion tests and all results presented
are the mean of 5 measurements. All measurements were
performed at ambient conditions and with a fixed suction time
of 3 seconds at 10 to 80 L/min (corresponding to pressure drops of
up to 20.1 kPa). Such high pressure drops are not representative
for the pressure drops to be attained by patients across dry powder
inhalers [18]. However, the purpose of this study was not to simply
conduct functionality experiments under conditions relevant to the
practice of dry powder inhalation. Rather, the aim is to obtain a
mechanistic insight into the effect of drug content, and it will
become clear from the results presented in this paper that this
requires detachment to almost complete removal of all drug
particles from the carrier surface. Finally it is to be noted that
changes in drug detachment that are measured in this way do not
always correlate to fine particle fractions, since large drug
agglomerates may be detached too. However, because the first
step to obtaining finely dispersed particles is drug detachment,
understanding the mechanisms behind drug particle liberation
from the carrier is highly relevant.
Sample Analysis
Collected samples of the salmeterol, fluticasone, budesonide and
salbutamol blends and carrier residues were spectrophotometri-
cally analysed at wavelengths of 228, 228, 243 and 225 nm,
respectively (Unicam UV-500, ThermoSpectronic, Cambridge,
UK). Salbutamol was dissolved in demineralised water and all
other drugs in ethanol. Samples were allowed to dissolve for at
least one hour. Prior to UV-analysis the samples in ethanol were
centrifuged for 5 minutes at 3000 rpm to obtain solutions free
from suspended lactose (Hettich Rotanta D-7200, Hettich AG,
Switzerland). Absorption values were corrected for any absorption
caused by the dissolution of lactose when applicable.
Statistical Analysis
A heteroscedastic 2-tailed Student’s t-test was performed using
Microsoft Excel 2010 to test the significance of the difference in
drug detachment at 20 and 50 L/min between formulations
containing 0.4% and 4% of drug.
Results
Content Uniformity
The highest RSD in drug content measured was 2.04%, and
therefore all blends prepared were sufficiently homogeneous and
considered suitable for the dispersion experiments.
SEM Imaging
SEM images presented in Figure 1 show that both bronchodi-
lator drugs salmeterol and salbutamol consist of plate like particles,
whereas the corticosteroids budesonide and fluticasone are more
irregularly shaped. In addition, the corticosteroids seem to contain
more submicron particles, although this is not reflected in the X10
values obtained from RODOS dispersion (Table 3). This suggests
that these fines are firmly attached to the coarser particles or
comprise only a negligible volume fraction.
The lactose carrier contains a notable amount of adhering
lactose fines after being subjected to the same mixing conditions as
the blends, despite the preceding classification procedure (Fig. 2,
0%). It is difficult to distinguish between these fines and the drug
particles, particularly at a relatively low magnification of
2506(Fig. 2, 0.1–4%). This limits the possibility to accurately
monitor the spatial distribution of the drug particles over the
carrier surface with SEM. At salmeterol contents of 1% and
higher, carrier surface irregularities become filled up and covering
of the carrier surface by drug particles becomes more apparent.
For the other drugs the observations from SEM were similar.
In Figure 3, representative carrier surface close-ups of 4%
mixtures are shown at the same magnification. No notable
differences in the degree of agglomeration between the different
drugs can be observed.
Pycnometry and Laser Diffraction Analysis
True density values and characteristic values for the primary
PSD of the drugs used in this study are presented in Table 3. PSDs
of salmeterol and fluticasone in the adhesive mixtures as released
from the carrier surface during the suspension experiments are
shown in Figure 4. With increasing drug content the median
diameter of the drug agglomerates on the surface increases. At
drug contents .1% continuous hollow drug particle networks
remained in suspension after dissolution of the lactose carrier, as
shown for 4% salmeterol in Figure 5. The X50 values of these
hollow networks did not deviate much from those of the carrier
crystals. Obviously, such values do not provide information on the
size of detachable drug agglomerates but only on the size of the
carrier particles, and therefore, these data are not shown. In many
cases the shapes of the carrier particles from which the networks
were detached remained recognisable after complete dissolution of
the lactose.
Drug Detachment Experiments
Drug detachment as function of flow rate for the four drugs
tested shows a less pronounced sigmoidal relationship at a drug
content of 0.4% than for the 4% blends (Fig. 6). At flow rates
below 30 to 35 L/min the relative amount of drug detached
Drug Content Effects on Powders for Inhalation
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decreases when the drug content is increased from 0.4 to 4%,
whereas at higher flow rates the effect is opposite. The difference
in drug detachment at 20 and 50 L/min between formulations
containing 0.4% and 4% of drug is statistically significant
(p,0.001) for all drugs used.
For salmeterol and fluticasone the relationship between drug
content and drug detachment at different flow rates has been
examined further by preparing blends with drug contents of 0.1%,
0.2%, 1% and 2% as well. For salmeterol, an increase in drug
content from 0.1% to 0.2% leads to a higher drug detachment for
all flow rates up to 60 L/min (Fig. 7). At flow rates from 10 to
30 L/min a maximum drug detachment is reached between drug
contents of 0.2 and 1%. Drug detachment at higher contents tends
to decrease for these flow rates before reaching a constant value at
the highest drug contents. At 50 and 60 L/min, drug detachment
continues to increase and approaches the 100% value at a drug
content of 4%. Different trends are observed for fluticasone (Fig. 7).
At all flow rates drug detachment decreases initially when the drug
content is increased, starting at 0.1%. After reaching a minimum
value at drug contents of 0.2% (at low flow rates) and 0.4% (at
high flow rates), an increase in detachment is obtained when the
drug content is further increased to 0.4% (low flow rates) and 1 to
2% (high flow rates), respectively. Further increasing the drug
content results in a decrease in detachment again at low flow rates,
whereas detachment continues to increase marginally at 50 and
60 L/min towards a maximum value obtained at 4% drug
content. It is difficult to draw unequivocal conclusions from these
differences in fluticasone detachment behaviour between drug
content ranges at the different flow rates, because the changes are
small and stay within a narrow range of at most 8% of the initial
drug content. From our experience with these drug detachment
experiments we know that environmental conditions (especially
relative air humidity) can very well account for differences of up to
5%, and therefore, some of these changes might not be physically
relevant in relation to the changes in drug content, even if
statistical significance could be proven.
A different representation of the drug detachment data at 60 L/
min from Figures 6 and 7 is given in Figure 8. With increasing
drug content the slope of the relationships decreases, which means
that the fraction of drug that is not detached from the carrier
decreases. This may be indicative for the saturation of active sites,
as explained previously for similar relationships [11]. Different
plateau values for the different drugs are reached upon extrap-
olation in the order of fluticasone.budesonide.salmeterol.sal-
butamol.
Figure 9 illustrates the role of mixing time as an interacting
variable for the effect of drug content on drug detachment. After a
relatively short mixing time of 2 minutes the absolute difference in
drug detachment between a drug content of 0.4 and 4% is at most
11% for salbutamol and 5% for budesonide. These differences
increase to 22% and 25%, respectively, after 60 minutes of mixing.
At a drug content of 0.4% longer mixing results in higher drug
detachment at 10 and 20 L/min for both drugs, whereas at higher
flow rates drug detachment decreases. With a drug content of 4%,
Figure 1. Representative SEM images of the four micronised drugs.
doi:10.1371/journal.pone.0071339.g001
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increasing the mixing time from 2–60 minutes results in a negative
effect on drug detachment at intermediate flow rates of 30 and
40 L/min, whereas at flow rates #20 and $50 L/min the effect is
negligible for both drugs.
Discussion
About the Occurrence of the Different Mechanisms
Drug agglomeration. It is reasonable to expect that more
drug agglomerates (with or without lactose fines) are formed, and
that their size as they are detached from the carrier during
dispersion increases when the drug content in the mixture is
increased. Such an expectation is supported by the data presented
in Figures 2–4. This results in a change of the ratio of separation to
binding forces in such a way that drug detachment is enhanced,
especially for devices relying primarily on inertial separation forces
such as the device used in this study [17]. An absolute
quantification of this effect based on the data from this study is
not possible, however. During the wet laser diffraction measure-
ments (Fig. 4) a slow decrease of the characteristic PSD descriptors
(X10, X50 and X90) was observed after the 12 minute period in
which the lactose carrier dissolved. This is likely the result of
partial deagglomeration of the drug particles in the liquid and it
may be expected that this process occurs during dissolution of the
lactose carrier as well. The deagglomeration process may further
be influenced by dissolution of fine lactose particles that have co-
agglomerated with the drug particles. The size distribution of the
agglomerates could thus depend on their strength in suspension,
which, in turn, is likely to depend on the degree of co-
agglomeration of the drug with lactose fines. The degree of
deagglomeration may vary for different drugs, which limits the
direct comparison between fluticasone and salmeterol in this
respect. Nevertheless, the measurements proved to be highly
repeatable, as may be concluded from the y-error bars in Figure 4.
In addition, the observed trend is the same for both drugs
investigated. Therefore, although the data may not be correct in
absolute sense, they certainly are indicative of drug particle
enlargement with increasing drug content. Furthermore, the
formation of drug layers and agglomerates is confirmed with
SEM, especially at drug contents .1% (Fig. 2 and 3).
Drug compression onto the carrier surface. An increased
effectiveness of press-on forces is difficult to measure, but SEM
images may be used to quantify at least the drug content above
which the propensity for this effect will increase. The complete
filling of irregularities in the carrier surface is approached within
the range of drug contents between 0.4 and 1% (Fig. 2). From this
concentration upward the efficacy of the mixing forces as press-on
forces is likely to increase, which, as explained in the introduction,
is expected to contribute in a negative way to the effect of drug
content on drug detachment during inhalation.
Saturation of active sites. Based on the results presented in
Figure 8 and the data presented in previous studies [10,11], the
occurrence of the saturation of active sites with an increasing drug
content seems very plausible. However, at low drug contents (i.e.
below theoretical monolayer carrier coverage) this effect is
expected to be strongly dependent on the degree of preferential
occupation of active sites: if no preferential occupation of active
sites occurs during mixing, then saturation of active sites is not
possible within this drug content range. Dispersion experiments do
not provide the ability to distinguish between the saturation of
Figure 2. Representative SEM images of the carrier after the
mixing process (0%) and of salmeterol blends. The percentage
indicates the salmeterol content of the mixture.
doi:10.1371/journal.pone.0071339.g002
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active sites, agglomeration effects and press-on effects. Therefore,
to definitively prove the occurrence of the saturation of active sites
it is necessary to measure differences in the relative amount of drug
attached to active sites (for example the non-detached drug
fraction after dispersion at 60 L/min) between the different drug
contents in the absence of agglomeration and press-on effects.
Because in this study at least agglomeration already occurs from
the lowest drug content used upward (as discussed), this is not
possible. Strong (indirect) indications for the occurrence of the
saturation of active sites as a result of changes in drug content have
never been presented along with definitive proof of the absence of
other mechanisms either. Therefore, although the saturation of
active sites is very likely to occur, it cannot be proven beyond
reasonable doubt with the current data presented and the
relevance of this mechanism to the overall effect of drug content
in this study remains uncertain.
To further illustrate this problem, several hypothetical relation-
ships between the residual drug content on the carrier after a drug
detachment experiment at 60 L/min and the initial drug content
in the blend are displayed in Figure 10. For the purpose of this
example we define active sites as sites where drug particles can
only be detached at flow rates .60 L/min through the inhaler
used in this study. Furthermore, we assume that 100% monolayer
coverage of the carrier corresponds to a drug content of 1.5% and
that the maximum binding capacity of active sites for the primary
drug particles corresponds to a drug content of 0.2%. In situation
1 the preferential occupation of active sites is complete, no
agglomeration or press-on effects occur and multilayer coverage of
the carrier by the drug does not result in the formation of new
active ‘apparent carrier surface sites’ by underlying drug layers.
Under such conditions the saturation of active sites is characterised
by a relationship that follows the ‘0% drug detached’ line (for
which y= x) until a plateau value is reached that is equal to the
binding capacity of active sites. The saturation of active sites
results in a positive effect on drug detachment at drug contents
.0.2%. In situation 2 completely non-preferential occupation of
active sites occurs (i.e. a random distribution of drug particles over
all carrier sites is obtained), which causes active sites to be
saturated only when the complete carrier surface is covered with a
drug monolayer. In this situation the saturation of active sites
results in a positive effect on drug detachment only at initial drug
contents .1.5% (i.e. the concentration at which the complete
surface is covered). In situation 3 completely preferential
occupation of active sites in combination with an increasing
effectiveness of press-on forces with increasing drug content causes
an increasing drug mass to be attached to ‘pseudo-active sites’
[19], thereby gradually increasing the total binding capacity of
active sites. In the case of multilayer coverage of the carrier,
underlying drug layers may also form new active sites to increase
their total binding capacity. This results in a higher drug
concentration after detachment at drug contents .0.2% com-
pared to relationship 1. Relationship 4 represents the situation in
which drug agglomeration dominates the overall effect of drug
content: a higher agglomeration potential of the drugs with
Figure 3. Representative SEM images of the 4% mixtures for the different drugs.
doi:10.1371/journal.pone.0071339.g003
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increasing drug content causes the ratio of separation to binding
force to increase due to agglomeration for an increasing fraction of
the drug mass. As a result, the saturation content of active sites (for
the primary drug particles) may never be reached after detach-
ment and saturation of active sites does not contribute to improved
drug detachment with increasing drug content. Relationship 5
displays an intermediate situation between situations 3 and 4. The
lower slope with increasing drug content is representative for a
larger fraction of the drug mass being detached. In the absence of
the exact binding capacity of active sites as a reference (which is
the situation in practice), situation 5 cannot be distinguished from
situation 4 when regarded individually. This means that the
increased drug detachment may be completely the result of either
agglomeration effects, or the saturation of active sites (with a
gradually decreasing degree of preferential occupation of active
sites with increasing drug content) or a combination of both.
Therefore, only in the absence of agglomeration effects such a
relationship, which is representative of those experimentally
determined for the different drugs (Fig. 8), would be proof of the
occurrence of the saturation of active sites.
About the Variables that Interact with the Effect of Drug
Content
The flow rate. The results presented in Figure 6 show that
flow rate interacts with the effect of drug content in a quantitative
and qualitative way. This could be explained by the flow rate
causing a shift in the balance of the different mechanisms behind
the effect of drug content on drug detachment. At low flow rates
(,30–35 L/min) the negative effect from press-on effects has to
dominate any positive contribution from agglomeration effects or
the saturation of active sites. At flow rates above 30–35 L/min a
dominance of agglomeration effects and the saturation of active
sites over press-on effects gives an opposite result. In the following
section it will be discussed that this finding is strongly dependent
on the chosen drug content range of 0.4 to 4%.
Because flow rate does not influence the properties of the
powder mixtures, the shift in the balance of the different
mechanisms concerns a change in their significance to drug
detachment. For example, a decrease in the drug fraction that is
only detached at flow rates .60 L/min due to the saturation of
active sites does not necessarily increase the fraction that is
detached at flow rates ,30 L/min. It may also just increase the
fraction that is exclusively detached at flow rates between 30 and
60 L/min. In that case, the saturation of active sites would be
significant to drug detachment only at flow rates .30 L/min. In a
following article (in preparation) the interacting effect of flow rate
will be discussed and explained in more detail.
The drug content range. As explained, the occurrence of
press-on effects and the saturation of active sites may be strongly
dependent on the range over which the drug content is changed. It
therefore determines their balance and thus the overall effect of
drug content on drug detachment. Strictly the drug content range
is not an interacting variable for the effect of drug content, but a
specific property of the variable itself. Therefore, this interaction is
an example of a conditional effect [20]. Its occurrence is confirmed
by the results presented in Figure 7, which shows both quantitative
and qualitative interactions. The difference between salmeterol
and fluticasone in this respect shows also a drug specific influence.
Figure 4. Agglomeration behaviour of salmeterol and flutica-
sone in the mixture with increasing drug content. Data are
obtained by laser diffraction in saturated aqueous drug solutions after
complete dissolution of the lactose carrier. Y-error bars represent
minimum and maximum values measured (n = 2).
doi:10.1371/journal.pone.0071339.g004
Figure 5. Salmeterol network in suspension after dissolution of
the lactose carrier from a 4% blend. The scale bar represents
60 mm.
doi:10.1371/journal.pone.0071339.g005
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In the discussion about the occurrence of the three mechanisms
it was reasoned that agglomeration is likely to occur starting at the
lowest contents used, and that press-on effects become relevant
from drug contents of 0.4% upwards. The concentration
dependent salmeterol detachment at flow rates up to and including
30 L/min presented in Figure 7 can therefore be explained with
an initial dominance of agglomeration effects (causing the initial
increase in drug detachment between 0.1 and 0.2–0.4%) followed
by a dominance of press-on effects with increasing drug content
(causing the decrease in drug detachment). Apparently, at higher
flow rates separation energies have become so high that the
increase in binding energy by press-on effects has become
insignificant. As discussed, the saturation of active sites may
contribute to the overall effect too, but their relevance is uncertain.
The trends observed for fluticasone detachment within the same
drug content range are not the same (Fig. 7). Considering the data
presented in Figure 4, agglomerate formation also occurs for
fluticasone. Apparently, the effect from agglomeration is balanced
by the effect of press-on forces and the saturation of active sites in a
different way as for salmeterol. A more effective redistribution of
fluticasone towards active sites, a different interaction with the
lactose fines that are still present on the carrier surface after sieving
or a higher effectiveness of equally high press-on forces due to drug
specific characteristics (which will be discussed further on) may
explain this difference.
The mixing time. The data presented in Figure 9 show that
mixing time interacts with the effect of drug content on drug
detachment in a quantitative way. The small difference in drug
detachment between 0.4% and 4% after 2 minutes of mixing for
both drugs indicates that mixing is the driving force for the three
mechanisms discussed. Within such a short mixing time insuffi-
cient ‘chance effects’ (i.e. drug redistribution towards active sites,
drug de- or re-agglomeration and compression of the drug
particles onto the carrier surface) seem to have occurred to
significantly influence drug detachment. Alternatively, if these
chance effects would have been sufficient to induce significant
agglomeration and press-on effects and the saturation of active
sites between 0.4 and 4% after 2 minutes of mixing, they would
have to counteract each other over the range of flow rates that is
applied. This is not very likely. Therefore, the mechanisms seem to
become more significant during prolonged mixing but to a
different extent, which magnifies any overall effect that results
Figure 6. Effect of drug content on drug detachment and its dependence on flow rate and drug type. The difference between the 0.4%
and 4% curves represents the effect of drug content on drug detachment at the different flow rates. The mixtures were prepared by 10 minutes of
mixing. The y-error bars represent maximum and minimum values measured (n = 5).
doi:10.1371/journal.pone.0071339.g006
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from their balance. It should be realised that the data from
Figures 6 and 7 (obtained with 10 minutes of mixing) are therefore
also to a great extent the result of the chosen mixing time, at least
with respect to the magnitude of the observed effects.
An increase in drug content from 0.4–4% causes a notable
interaction with the effect of mixing time on drug detachment too.
At higher concentrations, higher flow rates are required to achieve
the same relative amount of drug detached when mixing is
prolonged. This negative effect is likely the result of a dominance
of press-on effects. For the lower drug content, the effect of
prolonged mixing more explicitly depends on the flow rate. The
negative effect at the higher flow rates can be explained by a
dominance of press-on effects and the redistribution of drug
particles towards active sites. The positive effect at low flow rates
seems contradictory to the redistribution of drug particles towards
active sites, but it can be explained by agglomeration effects and
the migration of drug particles towards sites of low binding activity
nonetheless. The mixing forces cause partial agglomeration of the
drug particles with each other and with lactose fines. These
resulting larger particles are most easily detached due to a larger
ratio of separation to binding force. Hence, they are likely first
detached at low flow rates. Drug particles also find shelter from
collisional and frictional mixing forces in carrier surface irregu-
larities without necessarily being attached with a high binding
force. Because the drug particles do not find shelter from inertial
separation forces at these sites during inhalation, migration of
particles towards these sites may result in a higher ratio of
separation to binding force too and can thus be regarded as the
redistribution of drug particles towards sites with a low activity.
This process can very well occur concurrently with the redistri-
bution of drug particles towards highly active sites. Which
mechanism is most relevant for the effect of mixing time on drug
detachment for mixtures that contain low drug contents will be the
subject of a future study.
The type of drug. Previously presented values for the
cohesion-adhesion balance (CAB) of salbutamol, salmeterol,
fluticasone and budesonide in combination with alpha lactose
monohydrate are 0.63, 2.39, 0.22 and 0.82 respectively [21,22].
Although it has been described that CAB-values can be highly
Figure 7. Effect of drug content on drug detachment and its
dependence on flow rate and drug type. In addition to Figure 6,
the dependence on the drug content range is shown. The mixtures
were prepared by 10 minutes of mixing. ‘100% CC’ refers to the drug
concentration corresponding to a theoretical monolayer carrier
coverage. The y-error bars represent maximum and minimum values
measured (n = 5).
doi:10.1371/journal.pone.0071339.g007
Figure 8. Residual drug content after a drug detachment
experiment at 60 L/min as function of initial drug content. Data
are a different representation of the data presented in Figures 6 and 7.
The y-error bars represent minimum and maximum values measured
(n = 5).
doi:10.1371/journal.pone.0071339.g008
Figure 9. The effect of drug content on drug detachment and
its dependence on mixing time. Data are shown for salbutamol and
budesonide. The difference between the 0.4% and 4% curves for equal
mixing times represents the effect of drug content on drug detachment
at the different flow rates. The y-error bars represent maximum and
minimum values measured (n = 5).
doi:10.1371/journal.pone.0071339.g009
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batch dependent [23], it is expected that the choice for the
different drugs brings about a difference in adhesion and cohesion
characteristics. This is supported by Figure 8, in which a higher
plateau value indicates that the average binding force for that drug
to lactose is higher, or that the average separation force is lower
due to a lower tendency to form agglomerates (or both). In this
respect the low CAB-value (0.22) of fluticasone could be indicative
of a high intrinsic adhesion to lactose, whereas salmeterol (2.39)
would be more prone to form agglomerates which are more easily
detached [24]. However, the literature CAB-values for budesonide
and salbutamol are not in agreement with the trends observed in
Figure 8, and neither are the observations with SEM regarding the
degree of agglomeration in Figure 3 (visually there seems to be
hardly a difference in the degree of agglomeration between the
different drugs). The different plateau values for the drugs could
also be the result of a difference in their average particle mass,
which is the result of the PSD of the drug and its density. In a
classifier based test inhaler the ratio of separation to binding force
is lower for lighter particles and they will therefore be less likely to
detach during inhalation. This would result in a higher plateau
value in Figure 8. However, the drug with the highest calculated
average particle mass (i.e. fluticasone, Table 3) also has the highest
plateau value, and therefore, differences in the average particle
mass neither explain the different plateau levels. Other drug
specific characteristics that are of influence on the adhesive and
cohesive interactions, such as the observed differences in particle
shape and roughness, but also surface energy, moisture adsorption,
deformability (e.g. Young’s modulus, Poisson ratio) and electro-
static properties are thus more likely to be the cause of the
observed differences.
Regardless of the underlying mechanism, the difference in
cohesion and adhesion characteristics between the drugs is
expected to cause a different balance of mechanisms with a
change in drug content. For example, the saturation of active sites
may be more pronounced for strongly adhesive drugs, especially
when the drug content is increased beyond monolayer coverage of
the carrier surface. For strongly cohesive drugs, however,
agglomeration effects may be more pronounced. The data
presented in Figures 6 and 9 show that the drug dependence of
the effect of a change in drug content is expressed not so much in
the direction as in the magnitude of the effect. However, from the
data presented in Figure 7 it follows that an independence of the
direction of the effect from the drug properties can be a result of
the chosen drug content range. For example, a change in drug
content from 0.1–0.4% results in opposite effects on drug
detachment between salmeterol and fluticasone at flow rates of
40 L/min and higher. Therefore, the type of drug causes both
qualitative and quantitative interactions with the effect of drug
content, depending on the drug content range.
Other variables. The results from this study may be a
consequence of the choice for other variables as well. For example,
the dispersion principle of the test inhaler used relies mostly on
inertial separation forces. This likely enhances the contribution of
agglomeration effects to the overall balance of effects. Further-
more, the coarse crystalline carrier fraction used may cause higher
press-on forces than a finer or granulated carrier fraction. The
negative contribution of an increased effectiveness of these forces
to the overall balance of mechanisms in this study may therefore
have been more dominant than will be the case for other carrier
materials. The opposite may be true for the low shear mixing
process and small batch size that was used. Finally, the drug
contents at which certain effects have been observed are likely
biased by the presence of lactose fines on the carrier surface after
the sieving procedure. This may especially be true at low drug
contents, where the lactose fines comprise a significant part of the
total fine particle mass.
Practical Implications
Based on the results from this study it is conceivable that the
differences in drug content between commercially available
formulations result in a different dispersion behaviour. This is
especially relevant for drugs from the same manufacturer that are
available in different dose strengths. Furthermore, a drug to
lactose ratio of 1:67.5 (1.46%) is not used in any of the
formulations presented in Tables 1 and 2, which should stimulate
researchers to use other than historical reasons for the choice of a
certain drug to lactose ratio. Examples could be a certain desired
carrier coverage (monolayer or multilayer), the desire to make use
of the sheltering capacity of carrier surface irregularities or the
approximate maximum binding capacity of active sites for the
carrier-drug combination that is being used. In addition, it follows
from the discussion that the drug content can greatly affect the
balance of different mechanisms. This has to be taken into account
when investigating the influence of other variables on the
dispersion performance of adhesive mixtures.
In explaining the effect of added lactose fines on the dispersion
performance of adhesive mixtures, the same mechanisms as for the
effect of drug content may be expected. This means that also
quantitative and qualitative interactions of flow rate with the effect
of added fines can occur. This was demonstrated previously for
lactose fines with a similar size distribution to the drug particles
[20].
Conclusions
The effects of drug content on drug particle detachment from
lactose carriers can be explained with a balance between
agglomeration effects, press-on effects and the saturation of active
sites. The flow rate, the type of drug, mixing time and the drug
content range are shown to cause quantitative and qualitative
interactions, likely by shifting the balance between the mechanisms
in play. Our findings explain conflicting results that were
previously reported in literature regarding the effect of drug
Figure 10. Relationships between residual and initial drug
content for different hypothetical scenarios. Residual drug
content = drug content after a drug detachment experiment at 60 L/
min. Drug contents that equal the maximum binding capacity of active
sites and monolayer coverage are assumed to be 0.2% and 1.5%,
respectively. The relationships represent: 1) completely preferential
occupation of active sites, absence of effects from agglomeration,
press-on forces and layer formation; 2) same as situation 1 with
completely non-preferential occupation of active sites; 3) same as
situation 1 with effects from press-on forces and layer formation; 4)
same as situation 1 with a high degree of agglomeration; 5)
intermediate situation with unknown balance of mechanisms.
doi:10.1371/journal.pone.0071339.g010
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content on dispersion performance. They furthermore irrefutably
show that the choice for variables other than the ones under
investigation should not be based on historical reasons, but rather
on how they may interact with the primary variable(s) of interest.
A higher drug content may lower the significance of a mechanism
such as the saturation of active sites and can therefore shift the
balance of effects of other variables towards agglomeration or
press-on effects, as is shown for the effect of mixing time in this
study.
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